<SEC-DOCUMENT>0001654954-19-011732.txt : 20191015
<SEC-HEADER>0001654954-19-011732.hdr.sgml : 20191015
<ACCEPTANCE-DATETIME>20191015095445
ACCESSION NUMBER:		0001654954-19-011732
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191015
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191015
DATE AS OF CHANGE:		20191015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		191149733

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cvm_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
UNITED STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">WASHINGTON,
D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 8-K</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CURRENT
REPORT</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to Section 13 or 15(d) of the</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Securities
Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date of
Report (date of earliest event reported): October 15,
2019</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 16px">
CEL-SCI CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Exact
name of Registrant as specified in its charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Colorado</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">001-11889</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">84-0916344</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 20%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(State
or other jurisdiction of incorporation)</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 20%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Commission
File No.)</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 20%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(IRS
Employer Identification No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8229
Boone Blvd. #802</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Vienna, VA 22182</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Address
of principal executive offices, including Zip Code)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
</font><font style="font-family: Times New Roman; font-size: 13px;">Registrant&#x2019;s
telephone number, including area code:&#xA0; <font style="text-decoration: underline">(703)
506-9460</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
N/A</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Former
name or former address if changed since last report)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table;">
<div style="display: table-row;">
<div style="display: table-cell; width: 24px;"><font style="font-family: Times New Roman; font-size: 13px">&#x2610;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table;">
<div style="display: table-row;">
<div style="display: table-cell; width: 24px;"><font style="font-family: Times New Roman; font-size: 13px">&#x2610;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table;">
<div style="display: table-row;">
<div style="display: table-cell; width: 24px;"><font style="font-family: Times New Roman; font-size: 13px">&#x2610;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table;">
<div style="display: table-row;">
<div style="display: table-cell; width: 24px;"><font style="font-family: Times New Roman; font-size: 13px">&#x2610;</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-14c))</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #231F20; font-family: Times New Roman; font-size: 13px">
Securities registered pursuant to Section 12(b) of the
Act:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 20%; border-left: 0.5pt solid rgb(0, 0, 0); border-top: 0.5pt solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #231F20; font-family: Times New Roman; font-size: 13px">
Title of Each Class</font></div>
</td>
<td style="vertical-align: top; width: 20%; border-left: 0.5pt solid rgb(0, 0, 0); border-top: 0.5pt solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #231F20; font-family: Times New Roman; font-size: 13px">
Trading Symbol(s)</font></div>
</td>
<td style="vertical-align: top; width: 20%; border-color: rgb(0, 0, 0); border-style: solid; border-width: 0.5pt 0.5pt 2px;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #231F20; font-family: Times New Roman; font-size: 13px">
Name of Each Exchange on Which Registered</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 20%; border-left: 0.5pt solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Common
Stock</font></div>
</td>
<td style="vertical-align: top; width: 20%; border-left: 0.5pt solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CVM</font></div>
</td>
<td style="vertical-align: top; width: 20%; border-left: 0.5pt solid rgb(0, 0, 0); border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">NYSE
American</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (&#xA7;203.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (&#xA7;204.12b-2 of this chapter.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company &#x2610;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. &#x2610; <font style="color: #000000"><br></font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; break-after: page; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: rgb(255, 255, 255);">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
8.01&#xA0;&#xA0;&#xA0; Other Events</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 15, 2019, the Company issued a press release, filed as
Exhibit 99.1, concerning the recommendation of the Independent Data
Monitoring Committee (IDMC) for the Company&#x2019;s Phase 3 head
and neck cancer study of Multikine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
IDMC:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a)
Recommended to continue the trial until the appropriate number of
events has occurred.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<br>
</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item&#xA0;9.01&#xA0;&#xA0;&#xA0;
Exhibits</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold"><font style="font-family: Times New Roman; font-weight: bold;">Exhibit
Number</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font style="font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 87%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold"><font style="font-family: Times New Roman; font-weight: bold;">Description of
Document</font></font></font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="cvm_ex991.htm"><font style="font-family: Times New Roman; font-size: 13px">9</font></a><a name="_GoBack"><!--anchor--></a>9.1</div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 87%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">October
15, 2019 press release</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;<br>
</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">CEL-SCI CORPORATION</font></font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<font style="font-family: Times New Roman; font-size: 13px">Date:
October 15, 2019</font></td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ <font style="font-family: Times New Roman; font-size: 13px">Patricia B.
Prichep</font> &#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<font style="font-family: Times New Roman; font-size: 13px">Patricia B.
Prichep</font></td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Senior Vice
President of Operations</font></font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cvm_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 99.1</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 32px">
<font style="color: #7F7F7F">N</font><font style="font-variant: small-caps; color: #7F7F7F">EWS
RELEASE</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="img001.jpg"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><br></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 49%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8229
Boone Boulevard, Suite 802</font></div>
</td>
<td style="vertical-align: top; width: 51%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">COMPANY
CONTACT:</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Vienna,
VA 22182. USA</font></div>
</td>
<td style="vertical-align: top; width: 51%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Gavin
de Windt</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Telephone
(703) 506-9460</font></div>
</td>
<td style="vertical-align: top; width: 51%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
</font><font style="font-size: 13px;">www.cel-sci.com</font></font></div>
</td>
<td style="vertical-align: top; width: 51%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(703)
506-9460</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA
MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER
STUDY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Vienna, VA, October 15 , 2019</font> -- CEL-SCI Corporation
<font style="font-weight: bold">(NYSE American: CVM)</font>
announced today that the Independent Data Monitoring Committee
(IDMC) for the Company's pivotal Phase 3 head and neck cancer study
of its investigational immunotherapy Multikine* (Leukocyte
Interleukin, Injection) has completed its recent review of the
Phase 3 study data. The IDMC meets periodically to review the
safety and efficacy of the ongoing Phase 3 study.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
data from all 928 enrolled patients were provided to the IDMC by
the clinical research organization (CRO) responsible for data
management of this Phase 3 study. At the most recent IDMC meeting
in October 2019 the IDMC reviewed &#x201C;progression free and
overall survival and limited demographic and safety data available
for the aforementioned protocol.&#x201D;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
IDMC made the following recommendation:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The IDMC
recommendation &#x201C;is to continue the trial until the
appropriate number of events has occurred&#x201D;.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">IDMCs
are committees commonly used by sponsors of clinical trials to
protect the interests of the patients and the integrity of the
study data in ongoing trials, especially when the trials involve
patients with life threatening diseases, and when, as in cancer
clinical trials, they extend over long periods of
time.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About CEL-SCI Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
believes that boosting a patient&#x2019;s immune system while it is
still intact should provide the greatest possible impact on
survival. Therefore, in the Phase 3 study CEL-SCI treats patients
who are newly diagnosed with advanced primary squamous cell
carcinoma of the head and neck with the investigational product
Multikine first, BEFORE they receive surgery, radiation and/or
chemotherapy. This approach is unique. Most other cancer
immunotherapies are administered only after conventional therapies
have been tried and/or failed. Multikine (Leukocyte Interleukin,
Injection), has received Orphan Drug designation from the FDA for
neoadjuvant therapy in patients with squamous cell carcinoma
(cancer) of the head and neck.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
believes that this Phase 3 study is the largest Phase 3 study in
the world for the treatment of head and neck cancer. Per the
study&#x2019;s protocol, newly diagnosed patients with advanced
primary squamous cell carcinoma of the head and neck are treated
with the Multikine treatment regimen for 3 weeks prior to receiving
the Standard of Care (SOC) which involves surgery, radiation or
concurrent radiochemotherapy. Multikine is designed to help the
immune system &#x201C;see&#x201D; the tumor at a time when the immune
system is still relatively intact and thereby thought to better be
able to mount an attack on the tumor. The aim of treatment with
Multikine is to boost the body&#x2019;s immune system prior to SOC.
The Phase 3 study is fully enrolled with 928 patients and the last
patient was treated in September 2016. To prove an overall survival
benefit, the study requires CEL-SCI to wait until 298 events have
occurred among the two main comparator groups.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s experimental LEAPS technology is currently being
developed as a potential therapeutic vaccine for rheumatoid
arthritis and is supported by grants from the National Institutes
of Health. The Company has operations in Vienna, Virginia, and near
Baltimore, Maryland.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements with respect to Multikine and the Phase 3
clinical trial of Multikine in patients with advanced primary
squamous cell carcinoma of the head and neck. When used in this
press release, the words "intends," "believes," "anticipated,"
"plans" and "expects," and similar expressions, are intended to
identify forward-looking statements. Such statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. Factors that could cause or
contribute to such differences include an inability to duplicate
the clinical results demonstrated in clinical trials or nonclinical
studies, timely development of any potential products that can be
shown to be safe and effective, receiving necessary regulatory
approvals, difficulties in manufacturing any of the Company's
potential products, inability to raise the necessary capital and
the risk factors set forth from time to time in CEL-SCI&#x2019;s
filings with the Securities and Exchange Commission, including but
not limited to its report on Form 10-K for the year ended September
30, 2018. The Company undertakes no obligation to publicly release
the result of any revision to these forward-looking statements
which may be made to reflect the events or circumstances after the
date hereof or to reflect the occurrence of unanticipated
events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in
progress.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !F -<# 2(  A$! Q$!_\0
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M1BG[&A)7?-KROFY+:+7WM$[:[Z'M%%?'"_\ !9/PHPX\%>+#W^]!S_X]2_\
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MB-X-\9OXAUO5];@L;RUALWOKEI_)/EN752Q)'\!//I7'?\%JO^/GX=_[M_\
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M_P $W?%^DZ1^QKX1@NM4TVVF4W9:.6Z1'7-W-C()R*]R_P"%@Z#_ -!O2/\
MP,C_ ,:X>(J<WFN):3_B3_\ 2F>UP!BJ*X8RY.:O["EU7_/N)L5^//[<.GZQ
MIW[67CI=<$_VN74WE@,N?GMF_P!05_V?+V@8]".U?KC;^.=%N[A(HM8TN261
M@J(EW&6<GH ,\FL+XI?L_P#@SXU&W/BKPUI>MO:9$$EQ%^]B![!QAL>V<5Z?
M!_$4<DQDJ]:FY1E&VFZU3TOZ'SGBSP!4XSRF&#P>(4)TY\ROK%Z-6=M5O=.S
M]-;GY]_\$BM.UF?]I^XN; 3C28-(F75'&?*PQ7RE;MNWC(]E;WK]-JY[X<?"
MKPY\(M!_LSPSHNGZ)8[_ #&BM(0@=O[S'JQ]R2:VM3NGLM-N)HXS-)%&SK&.
MKD D#\:X^*L]CF^82Q<(<JLDEUTZOS/6\,."*G"F10RJM5]I/F<FULG*VD;Z
MV5OF[NRN?EW\>/@'\9?V1/\ @H'KGQ4\%^![OQG9:C?WFIZ?/!:27L %W&RR
MQS)$1(C(7?&< X4Y-=5_P\O_ &I_^B()_P"$YJ?_ ,77H'[$'_!6#4/VFOC;
MJVC^+K#PEX%T&PTE[N)Y;\K+)<":)!&9)2JG 9S@+GCVKZP_X:(^'_\ T//@
M[_P=6W_Q=?/^I^AGP?\ \/+_ -J?_HB"?^$YJ?\ \7575O\ @KO\>OA=#%J/
MC3X/66GZ,TRPF2>QOM-#L<G8LLA9=Q .!@]/:OOK_AHCX?\ _0\^#O\ P=6W
M_P 77R'_ ,%J?BMX7\<?LE:;::+XET#5[I?$MI*T%EJ,-Q($$-P"VU&)P,CG
MW%'R ^N?V>/C?IG[1_P7\/\ C71XIK>QUZV\]8)L>9;N"4>-L<95U89[XSWK
MX-_X. F/]H_"\9./*U,XSW_T:OHG_@CW936?[ WA(RHR">YOY8BW\2&\FP1[
M5\[?\' 2'^T/A>V#CR]3&<<9_P!&I+<#[5_8PM(G_9%^&),49/\ PB^G<[1_
MS[1UZ9]BA/\ RRC_ .^!7DW[&_C#2+/]DOX9Q2ZKIL<B>&-.5D:Z0%3]FCX(
MSP:])_X3G1?^@QI?_@7'_C4@?+__  4B_P""=VN_MN>)?!\VC:_HOAZTT&WN
MX+HW5O)+)(9FB*E%3 .-ASEAU%>[V_@R7X<_LOKX?GN5O9M"\+_V?)<*I43M
M%:^67 ))&=N<9/6OF?\ X*>_\%"?%G[)/BKP9_P@\_AG4K35[6\DOH;R+[2-
MT;0[,-&ZLO#MWY_"OI6P\87/Q#_98BU^\@CM;S7/"HU">&/.R)Y;3S&5<\X!
M8@9IZV _.3_@@3_R<7XK_P"Q47_TIAHH_P""!/\ R<5XK_[%1?\ TIAHIRW
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M_LR+3)M1GATE-8F0><))(I&D6.*%8XI-\S>5)\KE%X4;OFXJ[ ^<_P#AP?\
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MW!MIP1@@&O1** ..\0_!#1O$?BXZR\VKVD\YB:\ALM0EMK?43%_JS.B, Y7
M';< %;<H &R? FF/KVK:B]N);C7+2&QO1(=T<T,7F[%*GC_EO)GUSSTK8HH
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
